<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Anterior gradient-2 (AGR2) promotes <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e>, cell migration, and cellular transformation, and is one of the specific <z:chebi fb="2" ids="33699">mRNA</z:chebi> markers for circulating <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells in patients with <z:e sem="disease" ids="C0685938" disease_type="Neoplastic Process" abbrv="">gastrointestinal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated the feasibility of AGR2 as a potent antigen for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> immunotherapy against <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) cells using dendritic cells (DCs) transduced with a recombinant adenovirus harboring the AGR2 gene (AdAGR2) </plain></SENT>
<SENT sid="2" pm="."><plain>DCs transduced with a recombinant adenovirus encoding the AGR2 gene (AdAGR2/DCs) were characterized </plain></SENT>
<SENT sid="3" pm="."><plain>These genetically-modified DCs expressed AGR2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> as well as AGR2 protein at a multiplicity of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> of 1,000 without any significant alterations in DC viability and cytokine secretion (IL-10 and IL-12p70) compared with unmodified DCs as a control </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, AdAGR2 transduction did not impair DC maturation, but enhanced expression of HLA-DR, CD80, and CD86 </plain></SENT>
<SENT sid="5" pm="."><plain>AdAGR2/DCs augmented the number of IFN-Î³-secreting T-cells and elicited potent AGR2-specific cytotoxic T lymphocytes capable of lysing AGR2-expressing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines </plain></SENT>
<SENT sid="6" pm="."><plain>These results suggest that AGR2 act as a potentially important antigen for immunotherapy against <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> in clinical applications </plain></SENT>
</text></document>